• Channels
    • All News
    • Premium Content
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Law
    • Manufacturing
    • Marketing
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Adimab team ac­cus­es promi­nent MIT in­ves­ti­ga­tor Ram Sasisekha­ran of rip­ping off an­ti­bod­ies and pre­sent­ing them as his own

4 years ago
R&D

Be­lea­guered Bio­gen faces the mu­sic as a ris­ing cho­rus of crit­ics push for a trans­for­ma­tive ap­proach to M&A

4 years ago
Deals
Pharma

Mer­ck bets $2.2B on a small can­cer drug biotech, snatch­ing it out of the IPO line­up

4 years ago
Deals
R&D

Can­cer re­search groups urge FDA to over­haul stan­dards for ear­ly cell ther­a­py tri­als, cut­ting time and cost. But will 'pre-com­pet­i­tive' al­liances fly?

4 years ago
R&D
Pharma

Dana-Far­ber’s 4-year le­gal bat­tle shines a light on the ori­gins of PD-1 re­search — forc­ing a reck­on­ing on who pi­o­neered the land­mark can­cer break­through

4 years ago
People
R&D

Ab­b­Vie con­cedes an­oth­er PhI­II can­cer drug flop as glioblas­toma de­feats lat­est as­sault

4 years ago
R&D

Bet­ter than CAR-T? Al­ready prep­ping for a US launch, Mor­phoSys posts stel­lar DL­B­CL da­ta to field against No­var­tis, Gilead

4 years ago
R&D

An­a­lysts spot­light the win­ners — and losers — on AS­CO pre­view night

4 years ago
R&D
Pharma

As Dai­ichi Sankyo-part­nered breast can­cer drug march­es to­ward fin­ish line, As­traZeneca brings in Cana­di­an sci­en­tist Sunil Ver­ma to rev up R&D

4 years ago
People

J&J pol­ish­es up its new list of late-stage block­buster can­di­dates — and can­cer re­mains big

4 years ago
R&D
Pharma

A top ex­ec at strug­gling Bio­gen jumps ship for a new job

4 years ago
R&D

Pfiz­er, Mer­ck KGaA clinch need­ed ap­proval for Baven­cio, di­rect­ly com­pet­ing against Keytru­da in kid­ney can­cer

4 years ago
Pharma

Alzheimer’s R&D projects side­lined as Bio­gen’s ad­u­canum­ab shock shakes re­searchers to the core of their be­liefs

4 years ago
Bioregnum
Opinion

Sol­id Bio’s high­er gene ther­a­py dose for Duchenne MD runs smack in­to a fresh set of safe­ty is­sues -- shares tum­ble

4 years ago
R&D
Cell/Gene Tx

Dai­ichi Sankyo faces FDA chal­lenges on miss­ing da­ta, cred­i­bil­i­ty and safe­ty con­cerns in hunt for 2 new drug OKs

4 years ago
R&D
Pharma

They got bounced out of Alex­ion. Now David Hal­lal and Vikas Sin­ha are back with $150M and a fo­cus on cell and gene ther­a­pies

4 years ago
Financing
Startups

PhI may still be a killing field of fail­ure but PhI­II suc­cess rates have surged, sig­nal­ing tec­ton­ic shifts in bio­phar­ma R&D

4 years ago
R&D

Push­ing hard for block­buster re­turns, No­var­tis finds PhI­II da­ta to as­sert Mayzent boosts cog­ni­tive pow­ers in MS pa­tients

4 years ago
R&D

Take­da inks a pair of sales to No­var­tis and J&J for up to $5.7B, hand­ing over 485 staffers

4 years ago
Pharma

Till­man Gern­gross is­n't out to im­press you with biobucks, but here are 3 part­ner deals that should

4 years ago
People
Pharma

Pfiz­er buys a rare dis­ease biotech for $340M-plus, putting them on a path to com­pete with Bio­Marin

4 years ago
R&D
Pharma

$250M As­traZeneca spin­off preps leap in­to 3-way bat­tle with ti­tans for a rare dis­ease mar­ket that spans the globe

4 years ago
R&D

Top Med­Im­mune re­search ex­ec joins the team now run­ning Im­muno­core in wake of an R&D re­struc­tur­ing at As­traZeneca

4 years ago
People
R&D

Hit by set­backs, Lund­beck­'s Deb­o­rah Dun­sire inks a $400M cannabi­noid buy­out, adding a dis­cov­ery site

4 years ago
People
Deals
First page Previous page 143144145146147148149 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Content
  • Don't Miss
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Law
  • Manufacturing
  • Marketing
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints Company 2022

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
Endpoints News

Log in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET